<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-324 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-324</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-324</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-258439610</p>
                <p><strong>Paper Title:</strong> Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer</p>
                <p><strong>Paper Abstract:</strong> ABSTRACT Epidermal growth factor receptor (EGFR) mutation status differs according to ethnicity, gender, smoking history, and histology types. The present study aimed to evaluate EGFR mutation status in patients with non-small cell lung cancer (NSCLC) and further explore its association with clinical characteristics and prognosis in advanced NSCLC patients (Stage IIIB-IV). 238 NSCLC patients were enrolled in this study from October 2016 through December 2019. Patient characteristics and clinical data including age, gender, smoking history, histology types, tumor stage, survival status, and time were collected via electronic medical record system or telephone. 21 somatic mutations which spanned exons 18-21 of EGFR were detected using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) method, followed by analysis of links to clinical characteristics, progression-free survival (PFS) and overall survival (OS). 103 patients were detected harboring EGFR mutations among the 238 cases tested (43.3%), and exons 19 and 21 were the highest mutation frequencies, with 20.6% and 19.3% respectively. The EGFR mutation rate was much higher in female versus male (57.4% vs 31.5%, p <0.001), in non-smokers compared to smokers (56.8% vs 25.9%, p <0.001), and in those with adenocarcinoma than other histology types (48.3% vs 3.7%, p <0.001). For patients in advanced stage, median PFS was 11 months in patients harboring EGFR mutations, versus 4 months in patients with wild type EGFR (p <0.001); median OS was 24 versus 12 months (p <0.001). Never smoking (p = 0.042) and adenocarcinoma (p = 0.007) were independent favorable factors for EGFR mutations. Our data strengthen the findings of high prevalence of EGFR mutations in Asian patients with NSCLC. Mutations are prevalent in those patients who are female, adenocarcinoma, and have never smoked. Moreover, advanced EGFR mutation-positive patients have better PFS and OS than those with wild type EGFR.</p>
                <p><strong>Cost:</strong> 0.012</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e324.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e324.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>This study (Chinese NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION STATUS AND THE IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-center study of EGFR mutation prevalence and clinical impact in 238 Chinese NSCLC patients (predominantly adenocarcinoma), reporting overall prevalence, exon distribution, and correlations with clinical characteristics and outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION STATUS AND THE IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Chinese (East Asian)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>China (Sinopharm Dongfeng General Hospital, Hubei)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>238</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>43.3% overall; exon 19: 20.6% (most frequent); exon 21: 19.3%; exon 18: 2.5%; exon 20: 0.4%. (Total 103 mutation-positive patients out of 238)</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 deletions (multiple E746_A750 and related 19-Del variants), exon 21 point mutations (L858R, L861Q), exon 18 G719X (G719A/C/S), exon 20 mutations including T790M and S768I and insertion types (H773_V774insH; D770_N771insG; V769_D770insASV). Among advanced mutation-positive cases, 19-Del = 44% and L858R = 46% of mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Strongly more common in never-smokers: 56.8% of never-smokers had EGFR mutations versus 25.9% of current smokers (p < 0.001); never-smoker was an independent favorable factor (OR = 2.76, 95% CI 1.04-7.34, p = 0.042).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>More common in females (57.4% vs 31.5%, p < 0.001) in univariate analysis; however gender was not an independent predictor after adjustment for smoking and histology (multivariate p = 0.498).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>The paper notes a 'genetic divergence of EGFR mutations according to ethnicity' and higher frequency in Asian populations but does not propose a specific genetic/hereditary mechanism to explain ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>The authors suggest differential smoking habits (and sex hormones in the context of gender differences) might contribute to observed differences in mutation frequencies; smoking pattern differences are implied as a contributing lifestyle factor to ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>The paper discusses regional/clinical practice and testing differences (e.g., routine EGFR-based treatment in some Asian countries) and acknowledges methodological limitations (single-center, sample size) that may influence observed prevalence; no detailed alternative explanation (e.g., environmental exposures) is provided.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>NSCLC (predominantly adenocarcinoma; 88.7% adenocarcinoma in cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Cites prior data that activating EGFR mutations have ~68% response to EGFR-TKIs vs ~11% for wild-type (Lindeman et al.); in this cohort advanced EGFR-mutant patients showed median PFS 11 months vs 4 months for wild-type, and median OS 24 months vs 12 months for wild-type (substantial outcome benefit rather than raw response rate reported).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer', 'publication_date_yy_mm': '2023-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e324.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e324.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Literature comparisons (ethnic/regional)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Reported EGFR mutation prevalence in NSCLC across ethnic/regional populations (as cited in this paper)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper summarizes published EGFR mutation frequencies from multiple countries/regions, highlighting higher prevalence in Asian populations compared with many non-Asian populations and noting variability by region, gender, smoking history and histology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Multiple (Asian and non-Asian: Korea, Japan, China, Spain/European, Poland, Greece, Iran, Lebanon, Asia Pacific region, Middle East, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Multiple (Korea, Japan, China, Spain, Poland, Greece, Iran, Lebanon, Asia Pacific region, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported frequencies cited in the paper: Korea 36.3%; Spain 13.6%; Poland 10.6%; Greece 15.7%; Iran 36.7%; Lebanon 11.9%; Japan 53.9%. Also cited: a large Asian study including Chinese patients 50.2%; Asia Pacific multicenter survey 38.1%; up to 68.5% in female non-smokers with adenocarcinoma in some Asian subgroups.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Across studies exons 19 and 21 (19-Del and L858R) are reported as the most common mutations; uncommon mutations in exons 18 and 20 are also reported in referenced literature.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>Yes â€” paper cites specific country/region prevalences (see egfr_mutation_frequency). In summary: Asian populations (e.g., large Asian study 50.2%, Japan 53.9%, Korea 36.3%) generally show higher EGFR mutation prevalence than many European/Middle Eastern reports (Spain 13.6%, Poland 10.6%, Greece 15.7%, Lebanon 11.9%), with some non-Asian regions showing intermediate values (Iran 36.7%).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Consistent literature trend cited: EGFR mutations are more common in never-smokers across populations (paper cites this as a general favorable factor).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Consistent literature trend cited: EGFR mutations are more common in females across populations (paper cites this as a general favorable factor).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>The paper refers to 'genetic divergence' by ethnicity as an observed phenomenon but does not provide specific genetic/hereditary mechanistic hypotheses; no detailed genetic explanation is proposed in the text.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>The paper suggests that differential smoking habits (and possibly sex hormone differences linked to gender) may contribute to observed ethnic differences, implying lifestyle patterns could partly explain prevalence variations.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>The authors note regional/testing/practice differences and study design limitations (e.g., single-center cohorts, sample size) may influence reported prevalence; they do not present detailed analyses of detection bias, healthcare access or environmental exposures but acknowledge regional variability in practice.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>NSCLC with emphasis on adenocarcinoma (many cited studies focus on adenocarcinoma histology)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Cited literature indicates activating EGFR mutations associate with substantially better response to EGFR-TKIs (example cited: ~68% response in activating mutations per Lindeman et al.); the paper summarizes that EGFR-mutant patients generally derive improved PFS/OS with EGFR-TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer', 'publication_date_yy_mm': '2023-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). <em>(Rating: 2)</em></li>
                <li>A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). <em>(Rating: 2)</em></li>
                <li>EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. <em>(Rating: 2)</em></li>
                <li>EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. <em>(Rating: 1)</em></li>
                <li>Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. <em>(Rating: 1)</em></li>
                <li>EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>